Treatment of Acute CMV Infection

Clinical Context Determines Treatment Approach

Over 90% of congenital CMV infections are asymptomatic, and CMV-related complications are extremely rare in healthy individuals 2
The American Academy of Pediatrics and other guideline societies recommend that ganciclovir is the therapy of choice for CMV infections requiring treatment, with an induction dose of 6 mg/kg IV every 12 hours for 15-21 days, followed by maintenance valganciclovir 15 mg/kg PO every 12 hours for 6 weeks 3, 4
For CMV retinitis in AIDS patients, the Centers for Disease Control and Prevention recommends valganciclovir 900 mg PO twice daily for 21 days, then 900 mg once daily, with treatment choice individualized based on lesion location, severity, and immune status 5
For CMV colitis/esophagitis, the American Gastroenterological Association recommends diagnosis by endoscopic visualization of ulcerations plus biopsy showing characteristic intranuclear inclusions, with treatment using ganciclovir 6 mg/kg IV every 12 hours for 2-3 weeks 3, 4, 5
For CMV neurologic disease, the National Institute of Neurological Disorders and Stroke recommends requiring a compatible clinical syndrome plus CMV DNA in CSF or brain tissue, with standard ganciclovir dosing as above 5
For congenital CMV with CNS involvement, the American Academy of Pediatrics recommends ganciclovir 6 mg/kg IV every 12 hours for 15-21 days, followed by valganciclovir 15 mg/kg PO every 12 hours for 6 weeks, with monitoring of ganciclovir AUC₀₋₂₄ to achieve therapeutic levels in newborns 2

CMV IgM positivity does not confirm active disease, as it may represent past infection, false-positive result, or cross-reactivity with EBV, according to the Infectious Diseases Society of America 1
The Centers for Disease Control and Prevention recommends CMV IgG avidity testing to distinguish primary infection from reactivation when both IgM and IgG are positive 1, 2
PCR for CMV DNA in blood, tissue, or relevant body fluids is the gold standard for diagnosing active infection, as stated by the American Society for Microbiology 3, 4
Blood-based PCR for CMV is insensitive for gastrointestinal disease, and biopsy with immunohistochemistry and PCR is required, according to the American Gastroenterological Association 6

Ganciclovir AUC monitoring is recommended in neonates due to large pharmacokinetic variability, as stated by the American Academy of Pediatrics 2

Positive CMV IgM alone in an asymptomatic or mildly symptomatic immunocompetent patient does not warrant treatment, according to the Infectious Diseases Society of America 1
Subclinical CMV infection in IBD patients does not require treatment unless steroid-resistant, as stated by the American Gastroenterological Association 3, 4
CMV IgG positivity alone indicates past exposure and immunity, not active disease requiring treatment, according to the Centers for Disease Control and Prevention 1
Prophylactic chemoprophylaxis is not justified due to potential adverse events, as stated by the American Society of Transplantation 3